Pharmaceutically active sulfanilide derivatives

Details Pharmaceutically active sulfanilide derivatives Pharmaceutically active sulfanilide derivatives

2007-12-25

2007-12-25

Eyler, Yvonne (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

Reexamination Certificate

active

10399040

ABSTRACT:
The present invention relates to sulfanilide derivatives of formula (I), in which R1and R2are optionally substituted aryl and heteroaryl groups and the other variables are as defined in the claims, for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such sulfanilide derivatives. Said derivatives are useful in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to sulfanilide derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and/or vasopressin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin and/or vasopressin, including preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. The present invention is furthermore related to novel sulfanilide derivatives as well as to methods of their preparation.

REFERENCES:
patent: 5338755 (1994-08-01), Wagnon et al.
patent: 5756497 (1998-05-01), Bell et al.
patent: 2004/0072816 (2004-04-01), Quattropani et al.
patent: 0 469 984 (1992-02-01), None
patent: 0 526 348 (1993-02-01), None
patent: 1 414 887 (1975-11-01), None
patent: 96/22775 (1996-08-01), None
patent: 00 06340 (1999-02-01), None
patent: 99/67221 (1999-12-01), None
patent: 00/50391 (2000-08-01), None
patent: 00 51975 (2000-09-01), None
Bartoli. Pathophysiology of Na and water retention in liver cirrhosis and its correction with vasoconstrictors and aquaretics. Expert Opin, Ther.Patents (2006) 16 (1) 59-68.
Chemical Abstracts, vol. 55, No. 14, XP002162400, Jul. 10, 1961.
Chemical Abstracts, vol. 58, No. 6, XP002162458, Mar. 18, 1963, abstract only.
Chemical Abstracts, vol. 59, No. 9, XP002162459, Oct. 28, 1963, abstract only.
Chemical Abstracts, vol. 60, No. 9, XP002162460, Apr. 27, 1964, abstract only.
Chemical Abstracts, vol. 61, No. 13, XP002162461, Oct. 26, 1964, abstract only.
Chemical Abstracts, vol. 62, No. 13, XP002162462, Jun. 21, 1965, abstract only.
Chemical Abstracts, vol. 64, No. 1, XP002162463, Jan. 3, 1966, abstract only.
W. Baker, et al.: “Cyclic meso-ionic compounds. Part III. Further properties of the sydnones and the mechanism of their formation” Journal of the Chemical Society, pp. 1542-1551, 1950.
W. Patterson et al.: “Azobenzocycloheptenones. Part IV. An azodibenzotropone” Journal of the Chemical Society, No. 9, pp. 3468-3472, Sep. 1962.
A. Acero-Alarcon et al.: “Unusual ring closure reaction of amides with pyrimidines: novel stereoselective synthesis of hexahydroimidazo'1,2-c]pyrimidines”, SYNTHESIS, No. 12, pp. 2124-2130, Dec. 1999.
M.-R. Chang et al.: “Synthesis of 7-substituted indolo'3,2,-b]quinoline derivatives”, HETEROCYCLES, vol. 33, No. 1, pp. 147-152, 1992.
K. Goerlitzer et al.: Anellierte chinoline, 6. Mitt. 10H-indolo'3, 2-Archiv Der Pharmazie., vol. 318, pp. 852-861, 1981.
Mario Maggi et al.: “Human myometrium during pregnancy contains and responds to V1 vasopressin receptors as well as oxytocin receptors” Journal of Clinical Endocrinology and Metabolism, vol. 70, No. 4, pp. 1142-1154, 1990.
Ben E. Evans et al.: “Orally active, nonpeptide oxytocin antagonists” J. Med. Che., vol. 35, pp. 3919-3927, 1992.
M. Thibonnier et al.: “The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists” Adv. Rev. Pharmacol. Toxicol.., vol. 41, pp. 175-202, 2001.
Marc Thibonnier et al.: “Molecular pharmacology of human vasopressin receptors” Adv. Exp. Med. Biolog., vol. 449, pp. 251-276, 1998.
Christian Rivalle et al.: “Ethyl (4-N-acytaminopyridin-3-yl)glyoxylate and 5-azaisatin as new synthons for a route to various new polyheterocycles” Heterocyclic Chem., vol. 34, pp. 441-444, 1997.
Leslie W. Deady et al.: “Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors”, J. Med. Chem., vol. 40, pp. 2040-2046, 1997.
Robert Ramage et al.: “An acid labile arginine derivative for peptide synthesis: NG-2,2,5,7,8-pentamethylchroman-6-sulphonyl-L-arginine”, TETRAHEDRON, vol. 47, pp. 6353-6370, 1991.
John P. Wolfe et al.: “Simple, efficient catalyst system for the palladium catalyzed amination of aryl chlorides, bromides, and triflates”, J. Org. Chem., vol. 65, pp. 1158-1174, 2000.
Andrew J. Souers et al.: “Preparation of enantioenriched a-bromo acids incorporating diverse functionality”, SYNTHESIS, pp. 583-585, 1999.
Andrew P. Combs et al.: “N-arylation of sulfonamides on solid supports”, J. Comb. Chem., vol. 2, pp. 29-32, 2000.
U.S. Appl. No. 11/449,802, filed Jun. 9, 2006, Schwarz, et al.
K. Goerlitzer et al., “Anellierte chinoline, 6. Mitt. 10H-indolo'3,2-b]chinoline,” Archiv Der Pharmazie., vol. 318, pp. 852-861, 1981.

Affiliated with

Also associated with

Rating

Pharmaceutically active sulfanilide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutically active sulfanilide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active sulfanilide derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3890741